Federal Register / Vol. 77, No. 8 / Thursday, January 12, 2012 / Notices 1939 

Background and Brief Description 

Tobacco use remains the leading 

preventable cause of disease and death 

in the United States, resulting in 

approximately 440,000 deaths annually. 

Smokers die an average of 14 years 

earlier than non-smokers. Moreover, 

cigarette smoking costs more than $193 

billion; $97 billion in lost productivity 

plus $96 billion in health care 

expenditures. Although the prevalence 

of current smoking among adults in the 

United States has declined significantly 

since 1964, in more recent years (2004 

to 2010) these declines have slowed or 

stalled with 1 in 5 adults reporting 

current smoking. In addition, promotion 

of non-cigarette tobacco products is 

leading to increased diversity of tobacco 

product usage, including the use of 

multiple products. 

With passage of the Family Smoking 

Prevention and Tobacco Control Act 

(FSPTCA) in 2009, the Food and Drug 

Administration is legally mandated to 

regulate tobacco products for the 

protection of public health. Congress 

passed the FSPTCA to discourage 

tobacco use among minors and young 

adults, to encourage cessation among 

adult smokers and to reduce the public 

health burden of tobacco related disease 

in the U.S. Under the Tobacco Control 

Act, FDA has been granted broad 

authority to use the best available 

science to develop and implement 

effective strategies to protect the 

public’s health. FDA authority includes 

setting and enforcing standards for 

tobacco product ingredients and design, 

establishing good manufacturing 

practices, instituting tobacco product 

labeling and health warnings; 

prohibiting marketing that is misleading 

to consumers and developing 

enforcement authorities to act quickly 

and effectively to remove violating 

products. In addition, the FSPTCA gives 

FDA the authority to assert jurisdiction 

over cigars and other currently 

unregulated tobacco products. Finally, 

FDA’s regulatory authority involves 

considering whether the marketing of 

tobacco products might encourage 

people who don’t use tobacco products 

to begin using them, encourage people 

who might otherwise quit to continue 

using tobacco, or encourage former 

users to relapse. 

In order to ensure that FDA is in 

compliance with the Tobacco Control 

Act’s mandate to protect the public 

health, annual data collection is needed 

at least initially to monitor the benefits 

and potential adverse consequences of 

FDA’s regulatory actions, as the 

regulatory framework is being 

established. The FDA must regularly 

monitor patterns of tobacco product 

usage—novel tobacco products as well 

as cigarettes—to identify changes in 

susceptibility and rates of tobacco use 

initiation, perceptions regarding tobacco 

use, and rates of tobacco use cessation. 

Rather than develop a completely new 

system to monitor measures critical to 

FDA, and thereby increasing burden to 

the population, FDA has partnered with 

CDC to leverage the existing NATS 

system. While NATS has been redesigned to meet the critical data needs 

of the FDA, many of the measures are 

relevant to CDC’s National Tobacco 

Control Program (NTCP), and CDC also 

will use the NATS data to evaluate the 

NTCP. Many of the NATS questions 

reflect CDC’s key outcome indicators for 

evaluating tobacco control programs. 

CDC proposes to conduct three annual 

cycles of the National Adult Tobacco 

Survey (NATS) to collect data necessary 

to evaluate the effectiveness of FDA’s 

initial regulatory actions. The NATS 

will be a stratified, random-digit dialed 

telephone survey of noninstitutionalized adults 18 years of age 

and older. To yield results that are 

representative nationally, information 

will be collected from 56,250 landline 

respondents. In addition, to include the 

growing population of households that 

exclusively use cell phones and would 

be missed in a survey relying only on 

land-lines, information will be collected 

from 18,750 cell phone respondents 

who do not have a landline. To obtain 

the target number of completed 

telephone interviews, approximately 

166,000 respondents will be contacted 

for initial eligibility screening. 

Response is voluntary. Study results 

will have significant implications for 

the development and periodic 

adjustment of policies and programs 

aimed at preventing and reducing 

tobacco use in the United States. There 

are no costs to respondents except their 

time. 

ESTIMATED ANNUALIZED BURDEN HOURS

Type of respondent Form name Number of 

respondents 

Number of 

responses per 

respondent 

Average 

burden per 

response 

(in hours) 

Total burden 

(in hours) 

Adults ages 18 or older .................... Screener for land-line users (pp 67– 

78 of the NATS).

125,000 1 2/60 4,167 

Screener for cell phone users (pp 

79–86 of the NATS).

41,000 1 1/60 683 

National Adult Tobacco Survey (pp 

5–66 of the NATS)—landline.

56,250 1 20/60 18,750 

National Adult Tobacco Survey (pp 

5–66 of the NATS)—cell phone.

18,750 1 20/60 6,250 

Total ........................................... ........................................................... ........................ ........................ ........................ 29,850 

Dated: January 6, 2012. 

Kimberly Lane, 

Reports Clearance Officer, Centers for Disease 

Control and Prevention. 

[FR Doc. 2012–474 Filed 1–11–12; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Allergy and 

Infectious Diseases; Notice of Closed 

Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 


tkelley on DSK3SPTVN1PROD with NOTICES
1940 Federal Register / Vol. 77, No. 8 / Thursday, January 12, 2012 / Notices 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Allergy and Infectious Diseases Special 

Emphasis Panel; Strategies for the protection 

of Pregnant Women and Infants Against 

Infectious Diseases (R01) 

Date: February 2–3, 2012. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Crowne Plaza Washington DC– 

Silver Spring, Silver Spring, MD 20910. 

Contact Person: B. Duane Price, Ph.D., 

Scientific Review Officer, Scientific Review 

Program, DHHS/NIH/NIAID/DEA, Room 

3139, 6700B Rockledge Drive, MSC 7616, 

Bethesda, MD 20892, (301) 451–2592, 

pricebd@niaid.nih.gov. 

Name of Committee: National Institute of 

Allergy and Infectious Diseases Special 

Emphasis Panel; NIAID Investigator Initiated 

Program Project Applications (P01). 

Date: February 3, 2012. 

Time: 1 p.m. to 4 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6700B 

Rockledge Drive, Bethesda, MD 20817 

(Telephone Conference Call) 

Contact Person: Raymond Richard Schleef, 

Ph.D., Scientific Review Officer, Scientific 

Review Program, Division of Extramural 

Activities, National Institutes of Health/ 

NIAID, 6700B Rockledge Drive, MSC 7616, 

Bethesda, MD 20892–7616, (301) 451–3679, 

schleefrr@niaid.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.855, Allergy, Immunology, 

and Transplantation Research; 93.856, 

Microbiology and Infectious Diseases 

Research, National Institutes of Health, HHS) 

Dated: January 5, 2012. 

Jennifer S. Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2012–459 Filed 1–11–12; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Center for Complementary 

and Alternative Medicine; Notice of 

Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Center for 

Complementary and Alternative Medicine 

Special Emphasis Panel; Clinical Studies of 

CAM Therapies. 

Date: January 30, 2012. 

Time: 1:30 p.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, Two 

Democracy Plaza, 6707 Democracy 

Boulevard, Bethesda, MD 20892 (Telephone 

Conference Call). 

Contact Person: Hungyi Shau, Ph.D., 

Scientific Review Officer, National Center for 

Complementary and Alternative Medicine, 

National Institutes of Health, 6707 

Democracy Boulevard, Suite 401, Bethesda, 

MD 20892, (301) 402–1030, 

Hungyi.Shau@nih.gov. 

Name of Committee: National Center for 

Complementary and Alternative Medicine 

Special Emphasis Panel. 

Date: February 24, 2012. 

Time: 7 a.m. to 7 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Bethesda Marriott Suites, 6711 

Democracy Boulevard, Bethesda, MD 20817. 

Contact Person: Peter Kozel, Ph.D., 

Scientific Review Officer, NCCAM, 6707 

Democracy Boulevard, Suite 401, Bethesda, 

MD 20892–5475, (301) 496–8004, 

kozelp@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program No. 93.213, Research and Training 

in Complementary and Alternative Medicine, 

National Institutes of Health, HHS) 

Dated: January 5, 2012. 

Jennifer S. Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2012–460 Filed 1–11–12; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Library of Medicine; Notice of 

Meetings 

Pursuant to section 10(a) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App), notice is 

hereby given of a meeting of the Board 

of Scientific Counselors, Lister Hill 

Center for Biomedical Communications. 

The meeting will be open to the 

public as indicated below, with 

attendance limited to space available. 

Individuals who plan to attend and 

need special assistance, such as sign 

language interpretation or other 

reasonable accommodations, should 

notify the Contact Person listed below 

in advance of the meeting. 

The meeting will be closed to the 

public as indicated below in accordance 

with the provisions set forth in section 

552b(c)(6), Title 5 U.S.C., as amended 

for review, discussion, and evaluation of 

individual intramural programs and 

projects conducted by the National 

Library of Medicine, including 

consideration of personnel 

qualifications and performance, and the 

competence of individual investigators, 

the disclosure of which would 

constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Board of Scientific 

Counselors, Lister Hill Center for Biomedical 

Communications. 

Date: April 5–6, 2012. 

Open: April 5, 2012, 9 a.m. to 11:30 a.m. 

Agenda: Review of research and 

development programs and preparation of 

reports of the Lister Hill Center for 

Biomedical Communications. 

Place: National Library of Medicine, 

Building 38, 2nd Floor, Board Room, 8600 

Rockville Pike, Bethesda, MD 20892. 

Closed: April 5, 2012, 11:30 p.m. to 4:30 

p.m. 

Agenda: To review and evaluate personal 

qualifications and performance, and 

competence of individual investigators. 

Place: National Library of Medicine, 

Building 38, 2nd Floor, Board Room, 8600 

Rockville Pike, Bethesda, MD 20892. 

Closed: April 6, 2012, 8:30 a.m. to 10 a.m. 

Agenda: Review of research and 

development programs and preparation of 

reports of the Lister Hill Center for 

Biomedical Communications. 

Place: National Library of Medicine, 

Building 38, 2nd Floor, Board Room, 8600 

Rockville Pike, Bethesda, MD 20892. 

Contact Person: Karen Steely, Program 

Assistant, Lister Hill Center for Biomedical 

Communications, National Library of 

Medicine, Building 38A, Room 7S709, 

Bethesda, MD 20892, (301) 435–3137. 

ksteely@mail.nih.gov. 

Open: April 6, 2012, 10 a.m. to 11:30 a.m. 

Agenda: Review of research and 

development programs and preparation of 

reports of the Lister Hill Center for 

Biomedical Communications. 

Place: National Library of Medicine, 

Building 38, 2nd Floor, Board Room, 8600 

Rockville Pike, Bethesda, MD 20892. 

Contact Person: Karen Steely, Program 

Assistant, Lister Hill Center for Biomedical 

Communications, National Library of 

Medicine, Building 38A, Room 7S709, 

Bethesda, MD 20892, (301) 435–3137, 

ksteely@mail.nih.gov. 

Any interested person may file written 

comments with the committee by forwarding 

the statement to the Contact Person listed on 

this notice. The statement should include the 

name, address, telephone number and when 

applicable, the business or professional 

affiliation of the interested person. 

In the interest of security, NIH has 

instituted stringent procedures for entrance 


tkelley on DSK3SPTVN1PROD with NOTICES